Celularity Inc. Regains Nasdaq Compliance Following Successful Filing of Quarterly Report
Celularity Inc. has regained compliance with Nasdaq regulations, resolving prior filing delays and improving financial reporting processes.Quiver AI SummaryCelularity Inc. announced it has regained compliance...
Celularity Inc. Files Current Quarterly Report, Reports Significant Revenue Growth for Q3 2024
Celularity reported significant revenue growth for Q3 2024, filing its Form 10-Q and meeting Nasdaq compliance requirements.Quiver AI SummaryCelularity Inc. has filed its Quarterly Report on Form 10-Q...
Celularity Inc. Receives Nasdaq Notice for Non-Compliance with Continued Listing Requirements
Celularity Inc. faces Nasdaq non-compliance but plans to submit a compliance plan by January 20, 2025.Quiver AI SummaryCelularity Inc., a regenerative medicine company, announced on November 21, 2024,...